[1]
Motevalli, M.H., Taheri, S., Peiravian, F. and Yousefi, N. 2019. Cost-Effectiveness of Sorafenib for Metastatic Renal Cell Carcinoma: A Systematic Review. International Pharmacy Acta. 2, 1 (Dec. 2019), 2e10:1–6. DOI:https://doi.org/10.22037/ipa.v2i1.24856.